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Introduction {#acn350875-sec-0005}
============

Frontotemporal lobar degeneration (FTLD) is clinically, neuropathologically and genetically heterogeneous. Among clinical presentations are changes in behavior, personality, and language. Some patients also have motor neuron disease.[1](#acn350875-bib-0001){ref-type="ref"} The most common neuropathologic findings in FTLD are tauopathies or TDP‐43 proteinopathies.[2](#acn350875-bib-0002){ref-type="ref"}, [3](#acn350875-bib-0003){ref-type="ref"} The most common genetic causes of FTLD‐TDP are mutations in progranulin (*GRN*)[4](#acn350875-bib-0004){ref-type="ref"}, [5](#acn350875-bib-0005){ref-type="ref"} and chromosome 9 open reading frame 72 (*C9ORF72*).[6](#acn350875-bib-0006){ref-type="ref"}, [7](#acn350875-bib-0007){ref-type="ref"} Mutations in *GRN* account for about one fourth[8](#acn350875-bib-0008){ref-type="ref"}, [9](#acn350875-bib-0009){ref-type="ref"} and *C9ORF72* for about one half[10](#acn350875-bib-0010){ref-type="ref"} of familial FTLD‐TDP. Clinically, almost all patients with mutations in *GRN* have frontotemporal clinical syndromes, with only rare reports of motor neuron disease.[11](#acn350875-bib-0011){ref-type="ref"} In contrast, patients with *C9ORF72* hexanucleotide repeat expansions often have motor neuron disease with or without clinical features of frontotemporal dementia.[12](#acn350875-bib-0012){ref-type="ref"}

The neuropathologic features of FTLD‐TDP are focal cortical atrophy of frontal and temporal lobes with variable involvement of parietal lobe, as well as cytoplasmic inclusions in neurons and glia that are immunoreactive for TDP‐43.[13](#acn350875-bib-0013){ref-type="ref"} The relative density and distribution of neuronal and glial inclusions, as well as dystrophic neurites permits subtyping of FTLD‐TDP into Types A, B, and C, as well as less common subtypes.[14](#acn350875-bib-0014){ref-type="ref"} FTLD‐GRN is almost always Type A, while FTLD‐C9ORF72 can be Type B and less often Type A*.* [15](#acn350875-bib-0015){ref-type="ref"}

The pathogenesis of neurodegeneration in FTLD‐TDP remains poorly understood. Several pathomechanisms have been hypothesized for FTLD‐C9ORF72, including toxic gain of function of RNA, protein aggregation, and impairment of nucleocytoplasmic transport.[16](#acn350875-bib-0016){ref-type="ref"}, [17](#acn350875-bib-0017){ref-type="ref"} Microglial dysfunction has recently been suggested to play a role, based upon studies of *C9orf72* knock‐out mice.[18](#acn350875-bib-0018){ref-type="ref"} Mechanisms thought to play a role in FTLD‐GRN are based on the fact that progranulin has neurotrophic properties, while the proteolytic products of progranulin, the granulins, may be proinflammatory modulators.[19](#acn350875-bib-0019){ref-type="ref"} Given that FTLD‐C9ORF72 and FTLD‐GRN may have different pathogenic mechanisms, we aimed to study clinical and neuropathological differences that might be related to this fact. Several previous studies have addressed clinicopathological characteristics of FTLD‐TDP; however, few have stringently controlled for subtype. In this study, we hypothesize that different clinical features between GRN and C9orf72 could be driven by a differential role of microglia in neuroinflammation. To address this hypothesis, we measured microglial phenotypes based on density and morphology in cases of FTLD‐GRN and FTLD‐C9ORF72 with Type A TDP‐43 pathology.

Materials and Methods {#acn350875-sec-0006}
=====================

Case materials {#acn350875-sec-0007}
--------------

All cases were submitted for diagnostic studies and research to the brain bank for neurodegenerative disorders at Mayo Clinic in Jacksonville, Florida. We identified 17 cases of FTLD‐C9ORF72 with Type A TDP‐43 pathology and 15 cases of FTLD‐GRN. All cases were neuropathologically classified by a single neuropathologist (DWD), and genotyping was performed on DNA extracted from frozen brain tissue. For clinicopathological studies, cases were included only if they had good quality medical documentation and there was diagnostic concurrence by a minimum of two neurologists. The final set of cases for clinical comparisons was 13 FTLD‐C9ORF72 and 14 FTLD‐GRN. For quantitative microglial morphological studies, tissue from all brain regions had to be available for assessment. The final set of cases for pathologic studies was 11 FTLD‐C9ORF72 and 11 FTLD‐GRN. A summary of cases included in clinical and pathologic analyses are listed in Table [1](#acn350875-tbl-0001){ref-type="table"} and additional details are provided in Table [S1](#acn350875-sup-0003){ref-type="supplementary-material"}.

###### 

Summary of clinical and pathologic features of cases studied.

                 Demographics   Pathologic features   Clinical features                                                                                                
  -------------- -------------- --------------------- ------------------- ------ --------- ----- ------ ------ ----- ----- ----- ----- ----- -------- -------- ------- ----
  FTLD‐C9ORF72   1              Clin                  M                   76     880       III   1      Fahr   −     7     \+    −     −     \+       L = R    \+      AD
  2              Clin           M                     70                  880    0         0            \+     10    −     \+    \+    \+    L = R    −        bvFTD   
  3              Clin           M                     74                  780    II--III   0            −      6     −     \+    \+    \+    L = R    −        DLB     
  4              Clin           F                     83                  1020   III       0     LB     \+     5     \+    −     −     −     L = R    −        AD      
  5              Clin           M                     70                  1140   IV        1     LB     \+     5     \+    \+    −     −     L \> R   −        bvFTD   
  6              Clin           M                     80                  980    V         4     CAA    \+     5     \+    −     −     \+    L = R    −        AD      
  7              Clin+Path      M                     86                  940    II--III   0            \+     12    \+    −     \+    −     L = R    −        DLB     
  8              Clin+Path      M                     81                  1000   II        1            \+     7     \+    −     \+    \+    L = R    −        AD      
  9              Clin+Path      M                     73                  900    III--IV   0            \+     3     −     \+    \+    \+    ···      \+       bvFTD   
  10             Clin+Path      M                     71                  720    II--III   2            \+     6     −     \+    −     \+    L = R    \+       bvFTD   
  11             Clin+Path      M                     66                  1020   II        0            −      2     \+    \+    −     −     ···      −        DLB     
  12             Clin+Path      F                     84                  740    II--III   0     AGD    \+     9     \+    \+    \+    \+    L = R    \+       bvFTD   
  13             Clin+Path      M                     66                  1120   IV        0     PART   −      6     −     \+    \+    −     L = R    \+       bvFTD   
  14             Path           M                     72                  1280   II        0            −      ···   ···   ···   ···   ···   ···      ···      ···     
  15             Path           F                     90                  860    II--III   2            −      ···   ···   ···   ···   ···   ···      ···      ···     
  16             Path           M                     65                  840    II--III   0            −      ···   ···   ···   ···   ···   ···      ···      ···     
  17             Path           M                     55                  900    III--IV   1            −      ···   ···   ···   ···   ···   ···      ···      ···     
  FTLD‐GRN       18             Clin                  M                   56     780       0     1             \+    10    \+    −     −     \+       R \> L   \+      AD
  19             Clin           F                     59                  900    0--I      0            −      3     −     −     −     \+    L = R    \+       PNFA    
  20             Clin           F                     85                  660    0         0            \+     16    \+    −     −     \+    L \> R   \+       AD      
  21             Clin           M                     73                  940    0         1            \+     15    −     −     −     \+    L \> R   \+       PNFA    
  22             Clin+Path      F                     65                  1100   II        1            −      2     −     −     \+    −     L = R    \+       aPD     
  23             Clin+Path      M                     75                  680    I         1            \+     6     −     −     −     \+    L \> R   \+       PNFA    
  24             Clin+Path      F                     75                  660    0         0     VaD    \+     7     −     \+    −     \+    L \> R   \+       bvFTD   
  25             Clin+Path      M                     63                  900    0         0            \+     4     −     \+    −     −     L = R    \+       bvFTD   
  26             Clin+Path      M                     64                  1000   0         0            \+     5     −     −     \+    \+    L = R    \+       PNFA    
  27             Clin+Path      F                     64                  760    I         0     VaD    \+     8     −     −     \+    \+    L = R    \+       CBS     
  28             Clin+Path      M                     65                  940    0         0     tau    \+     3     −     −     \+    \+    L = R    \+       CBS     
  29             Clin+Path      F                     60                  1000   0         1            −      4     −     −     \+    −     R \> L   −        CBS     
  30             Clin+Path      F                     67                  880    0         0            −      3     −     \+    −     \+    L = R    \+       bvFTD   
  31             Clin+Path      F                     71                  1080   II        3            −      2     −     \+    \+    −     R \> L   \+       bvFTD   
  32             Path           M                     87                  660    0--I      0            \+     ···   ···   ···   ···   ···   ···      ···      ···     

Cases included in clinical comparisons of FTLD‐GRN and FTLD‐C9ORF72 are indicated by "Clin," those included in pathological studies by "Path." A subset of cases was used in both studies ("Clin + Path"). Abbreviations: M, male; F, female; Braak stage, Braak neurofibrillary tangle stage (range: 0 to VI); Thal phase, Thal amyloid phase (range: 0 to 5); HpScl, hippocampal sclerosis; Dur, disease duration; EPS, extrapyramidal signs; Lang, language impairment; FHx, family history of neurodegenerative disease; Dx, final clinical diagnosis, Fahr, globus pallidus calcification; LB, Lewy body disease; CAA, cerebral amyloid angiopathy; AGD, argyrophilic grain disease; PART, primary age‐related tauopathy; VaD, cerebrovascular disease; tau, incidental 4R tauopathy; AD, Alzheimer's disease; bvFTD, behavioral variant of frontotemporal dementia; DLB, dementia with Lewy bodies; PNFA, progressive nonfluent aphasia; aPD, atypical Parkinsonism; CBS, corticobasal syndrome.
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Clinical assessment {#acn350875-sec-0008}
-------------------

Cognitive and psychiatric features were abstracted from medical records of neuropsychological and psychiatric evaluations. The clinical diagnosis of included cases fulfilled the criteria for behavioral variant frontotemporal dementia (bvFTD),[20](#acn350875-bib-0020){ref-type="ref"} progressive nonfluent aphasia (PNFA),[21](#acn350875-bib-0021){ref-type="ref"} or corticobasal syndrome (CBS).[22](#acn350875-bib-0022){ref-type="ref"} Clinical asymmetry was considered present for cases with diagnosis of PNFA and CBS or by asymmetry in motor findings from neurologic examinations.

Genetic analyses {#acn350875-sec-0009}
----------------

Frozen brain tissue was used for genotyping. All FTLD‐C9ORF72 cases had hexanucleotide repeat expansions in *C9ORF72* using a repeat--primed polymerase chain reaction method to detect expansions of the GGGGCC hexanucleotide,[6](#acn350875-bib-0006){ref-type="ref"} and for most cases, the expansions were confirmed with Southern blotting.[23](#acn350875-bib-0023){ref-type="ref"} FTLD cases with *GRN* mutations were confirmed using Sanger sequencing.[5](#acn350875-bib-0005){ref-type="ref"}, [9](#acn350875-bib-0009){ref-type="ref"}

Microscopic pathology {#acn350875-sec-0010}
---------------------

Samples from the middle frontal gyrus (mFCtx), superior temporal gyrus (sTCtx), inferior parietal cortex (iPCtx), primary motor cortex (MCtx), hippocampus, basal ganglia, and medulla were cut at 5 *µ*m thickness, mounted on glass slides and stained with hematoxylin and eosin (H&E). Thioflavin‐S fluorescent microscopy was performed to evaluate senile plaques and neurofibrillary tangles. A Braak neurofibrillary tangle stage and a Thal amyloid phase were derived from quantitative data, as described previously.[24](#acn350875-bib-0024){ref-type="ref"}

The neuropathologic assessment included immunohistochemistry for phospho‐TDP‐43 or an antibody to a neoepitope in the midregion of TDP‐43.[25](#acn350875-bib-0025){ref-type="ref"} The TDP‐43 Type A was assigned to each case using features described in the harmonized classification.[14](#acn350875-bib-0014){ref-type="ref"} All cases had neuronal cytoplasmic inclusions, short and thin dystrophic neurites in predominantly upper cortical layers, neuronal intranuclear inclusions and perivascular astrocytic inclusions.[26](#acn350875-bib-0026){ref-type="ref"}

Immunohistochemistry {#acn350875-sec-0012}
--------------------

Immunohistochemical studies were performed as previously described.[27](#acn350875-bib-0027){ref-type="ref"} Histologic sections and immunostained sections were quantified with digital image analysis. Sections were immunostained using antibodies to phosphorylated TDP‐43 (pS409/410, clone 11‐9, 1:5000, Cosmobio, Tokyo, Japan), ionized calcium‐binding adaptor molecule‐1 (IBA‐1) (rabbit IG, 1:3000, Wako Chemicals, USA), CD68 (clone KP1, 1:1000, DAKO/Agilent), and glial fibrillary acidic protein (GFAP) (clone GA‐5, 1:5000, BioGenex). All immunohistochemistry was performed on a DAKO AutostainerPlus (DAKO, Santa Clara, CA) with the DAKO EnVisionTM + system‐HRP (diaminobenzidine). Normal goat serum (1:20 in TBST; Sigma, St Louis, MO, USA) was used to block non‐specific antibody binding, and 3, 3\'‐diaminobenzidine (DAB) as chromogen.

Image analysis {#acn350875-sec-0013}
==============

Digital microscopy methods have been previously described.[28](#acn350875-bib-0028){ref-type="ref"} Briefly, immunostained sections were scanned on an Aperio ScanScope XT slide scanner (Leica Biosystems Aperio, USA) producing high resolution digital images. Analyses were performed using Aperio ImageScope software in defined regions of interest (ROIs). A color deconvolution algorithm was used to count the number of pixels that had strong immunoreactivity. The output was percentage of strong positive pixels relative to the total area of the ROI. For digital analysis of the hippocampus, several ROIs were defined, including the entire hippocampus, the dentate fascia, CA4 sector, and the parahippocampal gyrus.

For microvacuolation analyses, H&E sections of mFCtx, sTCtx, and parahippocampal gyrus were evaluated. The percentage of the area occupied by microvacuolation was assessed in cortical layer II as the number of weak positive pixels divided by the total number of positive pixels according to previously published methods.[29](#acn350875-bib-0029){ref-type="ref"} Severity of microvacuolation was also assessed by semiquantitative scores (none, mild, moderate or severe), and these results were similar to those obtained by image analysis (Fig. [S1](#acn350875-sup-0001){ref-type="supplementary-material"}).

For measurement of cortical thickness in mFCtx and sTCtx, ImageScope ruler tool was used by drawing a line perpendicular to the pial surface and the gray--white junction.

Quantitative analysis of microglial phenotypes {#acn350875-sec-0014}
----------------------------------------------

Digital image analysis was used to assess microglial density based on signal intensity in cell bodies and processes. To further investigate the role of microglia in FTLD‐TDP, we performed qualitative morphologic characterization of different microglia phenotypes using the Aperio counting tool for manual labeling of IBA‐1--positive or CD68--positive microglia in fixed‐sized ROI. Digital image analysis and manual counting of IBA‐stained sections gave comparable results (Fig. [S2](#acn350875-sup-0002){ref-type="supplementary-material"}). Individual microglial subpopulations were assessed in mFCtx, a severely affected region, and compared to MCtx, a minimally affected region and in the subcortical white matter. Microglia were categorized as ramified, elongated, rod‐shaped or ameboid (Fig. [1](#acn350875-fig-0001){ref-type="fig"}). Dystrophic microglia had evidence of fragmentation or beading of cell processes according to the criteria of Streit and Braak.[30](#acn350875-bib-0030){ref-type="ref"} Elongated cells had a polarized appearance with minimal branching, with rod--shaped nuclei, and process lengths between 75--150 *µ*m. The number of IBA‐1--positive ameboid, ramified, elongated, and dystrophic microglia were counted in each ROI. Cells were divided into CD68‐low, which lacked immunostaining of cell processes, but had perinuclear granules (Fig. [1](#acn350875-fig-0001){ref-type="fig"}) and CD68‐high, which had immunostaining of cell processes. Microglial counts in defined ROIs were made by two observers, one blinded (SFR) to all clinical, genetic and pathologic information. Five neurologically normal individuals, matched for age and sex, were used as controls for this analysis (Table [S2](#acn350875-sup-0003){ref-type="supplementary-material"}).

![Microglial morphologic differences in FTLD‐GRN and FTLD‐C9ORF72. Examples of microglial phenotypes with CD68 immunohistochemistry: (A) typical microglia in neurologically normal control; microglial subtypes: CD68‐low (B), CD68‐high (C), ameboid (D), rod‐shaped (E), and microglia with condensed nuclei (F). Examples of microglial phenotypes with IBA‐1 immunohistochemistry: ramified microglia (G, H), elongated (I), dystrophic (J), and ameboid microglia (K, L). Scale bar = 30 *µ*m.](ACN3-6-1782-g001){#acn350875-fig-0001}

Statistical analyses {#acn350875-sec-0015}
--------------------

SigmaPlot (Systat Software, San Jose, CA) was used for statistical analyses. Due to small sample sizes, non‐parametric Kruskal--Wallis analysis of variance (ANOVA) on ranks was performed on quantitative measures and differences in median values were assessed. Post hoc pairwise comparisons were performed between groups using Mann--Whitney rank sum test. For categorical data (sex, presence or absence of extrapyramidal signs, and symmetry/asymmetry of neuroimaging findings), a Chi‐squared test was used to compare group differences. Fisher's exact test was used for pairwise categorical data when the count was less than 5. Correlative analysis was performed using Spearman rank order correlation. A *P*‐value of \< 0.05 was considered statistically significant. Given that FTLD‐GRN tended to have more women and FTLD‐C9ORF72 to be older, analyses were also adjusted for age and sex in a multiple logistic regression models assessing clinical differences, such as memory impairment similar adjustments were made in multiple linear regression analyses for Braak stage.

Results {#acn350875-sec-0016}
=======

Clinical comparison of FTLD‐GRN and FTLD‐C9ORF72 {#acn350875-sec-0017}
------------------------------------------------

### Summary statistics of cases used in clinical analyses {#acn350875-sec-0018}

A summary of demographic, genetic and clinical information on FTLD‐GRN and FTD‐C9ORF72 is shown in Table [2](#acn350875-tbl-0002){ref-type="table"}. The median age at death was 65 years for FTLD‐GRN and 74 years for FTLD‐C9ORF72 (*P* = 0.011). There were no statistically significant differences between the two groups with respect to median disease duration and male‐to‐female ratio; but there were more women in FTLD‐GRN (57%) than FTLD‐C9ORF72 (27%). This observation fits with a recent meta‐analyses showing that FTLD‐GRN is more common in women than men.[31](#acn350875-bib-0031){ref-type="ref"}

###### 

Comparison of clinical features in FTLD‐GRN and FTLD‐C9ORF72.

                                                                               FTLD‐GRN (*N* = 14)   FTLD‐C9ORF72 (*N* = 13)   *P*‐value
  ---------------------------------------------------------------------------- --------------------- ------------------------- -----------
  Demographic characteristics                                                                                                  
  Sex (number \[percent\] of men)                                              6 (43%)               11 (81%)                  0.06
  Age at death                                                                 65 (62, 74)           74 (70, 82)               0.01
  Disease duration                                                             4 (3, 8)              6 (5, 8)                  n.s.
  Clinical features                                                                                                            
  Behavior (apathy/disinhibition)[a](#acn350875-note-0004){ref-type="fn"}      4 (28%)               8 (62%)                   n.s.
  Memory disorder                                                              2 (14%)               8 (62%)                   0.02
  Progressive nonfluent aphasia                                                4 (29%)               0 (0%)                    n.s.
  Progressive aphasia, not otherwise specified                                 3 (14%)               2 (15%)                   n.s
  Apraxia                                                                      3 (21%)               0 (0%)                    n.s.
  Limb dystonia                                                                2 (14%)               0 (0%)                    n.s.
  Alien hand syndrome                                                          1 (7%)                0 (0%)                    n.s.
  Clinically asymmetry                                                         9 (63%)               2 (15%)                   0.03
  Limb rigidity or bradykinesia                                                6 (43%)               7 (54%)                   n.s.
  Asymmetric atrophy on neuroimaging[a](#acn350875-note-0004){ref-type="fn"}   7 (50%)               1 (8%)                    0.03

Data are displayed as median (25th percentile, 75th percentile) or percent of patients with the specific feature, unless otherwise noted. Significant values (*P* \< 0.05) or those trending (*P* \< 0.10) are indicated. n.s., not significant.

Percentage for patients on which information is available. Clinically asymmetry was considered as clinical diagnosis was PNFA, CBS, laterality of extrapyramidal sign.
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### Asymmetric clinical syndromes and neuroimaging findings {#acn350875-sec-0019}

The asymmetrical clinical syndrome of CBS was noted in three of 14 patients (21%) with FTLD‐GRN, but in none of the FTLD‐C9ORF72 patients. Available MRI or CT images (14 for FTLD‐GRN and 11 for FTLD‐C9ORF72) showed asymmetrical cortical atrophy in only one patient with FTLD‐C9ORF72, but in seven (50%) patients with FTLD‐GRN (Table [2](#acn350875-tbl-0002){ref-type="table"}).

Language disorders {#acn350875-sec-0020}
------------------

Progressive aphasia (four PNFA and two progressive aphasia not otherwise specified) was noted in six of 14 patients with FTLD‐GRN, but in only three of 13 FTLD‐C9ORF72 patients. One patient appeared to have logopenic aphasia, and one patient appeared to have semantic components. A receptive component could not be excluded confidently. The remainder clearly had progressive aphasia, but could not be further subtyped.

### Amnestic clinical syndromes and extrapyramidal signs {#acn350875-sec-0021}

Amnestic dementia was based on neuropsychological evaluations and considered for patients where memory complaints were the predominant feature. Alzhiemer dementia was in the clinical differential diagnosis of some of these patients. Memory problems overshadowed other clinical features of FTLD, such as behavioral and language problems. Amnestic dementia (AD) was prominent in two patients (14%) with FTLD‐GRN, but in eight patients (62%) with FTLD‐C9ORF72. AD was the clinical diagnosis of four of eight FTLD‐C9ORF72 patients (Table [1](#acn350875-tbl-0001){ref-type="table"}). In FTLD‐C9ORF72, prominent memory problems were noted in four patients with dementia with Lewy bodies (DLB) (31%), and these patients also had extrapyramidal signs and visual hallucinations. The frequency of extrapyramidal signs in the entire cohort was similar in FTLD‐GRN and FTLD‐C9ORF72 (Table [2](#acn350875-tbl-0002){ref-type="table"}).

### Effects of age and Alzheimer type pathology on clinical features {#acn350875-sec-0022}

To determine potential confounding variables accounting for observed differences in clinical syndromes and neuroimaging findings, we addressed possible contributing pathologic features, such as brain weight, Thal amyloid phase, Braak neurofibrillary tangle (NFT) stage, and presence of hippocampal sclerosis (HpScl). There were no differences between FTLD‐GRN and FTLD‐C9ORF72 for age at death, disease duration, brain weight, frequency of HpScl or Thal amyloid phase. On the other hand, the median Braak NFT stage was greater (*P* \< 0.001) in FTLD‐C9ORF72 than in FTLD‐GRN. To adjust for the effects of age at death and sex on differences in Braak NFT stage, a multiple linear regression model showed higher (*P* = 0.011) Braak NFT stage in FTLD‐C9ORF72 compared with FTLD‐GRN.

### TDP‐43 pathology {#acn350875-sec-0023}

To assess differences in TDP‐43 pathology histological sections from the mFCtx, sTCtx, iPCtx and hippocampus were assessed and scored semiquantitatively as either present or absent. The density of phospho‐TDP‐43 pathology was also assessed with image analysis. There were no significant differences in TDP‐43 pathology in MCtx (not shown); however, densities of TDP‐43 pathology tended to be greater in FTLD‐GRN than FTLD‐C9ORF72 in mFCtx, sTCtx and iPCtx, (Fig. [2](#acn350875-fig-0002){ref-type="fig"}). On the other hand, FTLD‐C9ORF72 had greater TDP‐43 density in the hippocampus than FTLD‐GRN (*P* = 0.002). In subregions of the hippocampus, TDP‐43 density was significantly greater in dentate gyrus (*P* \< 0.001) and CA4 sector (*P* \< 0.001) in FTLD‐C9ORF72 compared with FTLD‐GRN.

![TDP‐43 burden in FTLD‐GRN and FTLD‐C9ORF72. TDP‐43 burden was calculated as the proportion of the total area with positive signal using pTDP‐43 immunohistochemistry in mFCtx (A), sTCtx (B), iPCtx (C), and hippocampus (D). Representative images of TDP‐43 pathology in dentate fascia and endplate in FTLD‐GRN (E) and FTLD‐C9ORF72 (F). Note the sparse neuronal cytoplasmic inclusions in FTLD‐GRN and more numerous inclusions in FTLD‐C9ORF72. Quantitative analysis shows significantly greater TDP‐43 burden in FTLD‐C9ORF72 compared with FTLD‐GRN in both dentate fascia (DF) (G) and endplate (CA4) (H). Box plots show median (line) and 25th and 75th percentiles; whiskers show 10th and 90th percentiles. Scale bars in (B) = 200 *µ*m. MFCtx, middle frontal gyrus; sTCtx, superior temporal gyrus; iPCtx, inferior parietal cortex; hippocampus, entire area of hippocampus. Bars indicate *P* \< 0.05 with Mann--Whitney *U* test.](ACN3-6-1782-g002){#acn350875-fig-0002}

### Cortical thickness {#acn350875-sec-0024}

We assessed cortical thickness in mFCtx and sTCtx. FTLD‐GRN had significant atrophy of the mFCtx (*P* = 0.036) (Table [3](#acn350875-tbl-0003){ref-type="table"}). The cortical thickness in the sTCtx was not significantly different.

###### 

Cortical thickness and CD68--positive microglia FTLD‐GRN and FTLD‐C9ORF72.

                                                    FTLD‐GRN                                                    FTLD‐C9ORF72        Ctrl                                                  *P*‐value
  ------------------------------------------------- ----------------------------------------------------------- ------------------- ----------------------------------------------------- -----------
  Cortical thickness (mFCtx)                        1845 (1605, 1959)[2](#acn350875-note-0007){ref-type="fn"}   2070 (1800, 2460)   2695 (2217, 2697)                                     0.036
  Comparison of CD68--positive microglia (mm^2^)                                                                                                                                          
  CD‐68 low                                         24 (16, 41)                                                 24 (14, 35)         18 (8, 20)                                             
  CD68‐high                                         5 (2, 16)                                                   8 (4, 21)           59 (50, 68)[1](#acn350875-note-0006){ref-type="fn"}   0.002
  Ameboid                                           1 (0, 6)                                                    1 (0, 1)            1 (1, 3)                                               
  Rod‐shaped                                        7 (2, 12)[2](#acn350875-note-0007){ref-type="fn"}           2 (1, 4)            1 (0, 1)                                              0.02
  Condensed nucleus                                 9 (4, 14)[3](#acn350875-note-0008){ref-type="fn"}           1 (0, 1)            1 (0, 1)                                              \<0.001
  Comparison of IBA‐1--positive microglia (mm^2^)                                                                                                                                         
  Ramified                                          50 (25, 175)                                                75 (25, 125)        52 (52, 67)                                            
  Ameboid                                           3 (3, 7)[2](#acn350875-note-0007){ref-type="fn"}            1 (0, 3)            1 (0, 1)                                              0.01
  Rod‐shaped                                        50 (13, 150)[2](#acn350875-note-0007){ref-type="fn"}        13 (0, 50)          0 (0, 1)                                              0.009
  Dystrophic                                        188 (113, 250)                                              250 (200, 312)      0 (0, 0)[1](#acn350875-note-0006){ref-type="fn"}      0.001

Cortical thickness measured in middle frontal gyrus (mFCtx) (expressed in mm (millimeters)). Manual counts of CD68‐positive microglia and IBA‐1‐positive microglia in mFCtx in FTLD‐GRN and FTLD‐C9ORF72 with respect to different morphologic subtypes. All data are displayed as median (25th percentile, 75th percentile). *P*‐value for ANOVA on Ranks comparison of all three groups.

Ctrl versus FTLD.

GRN versus Ctrl.

GRN versus Ctrl and C9.
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### Neocortical microvacuolation {#acn350875-sec-0025}

The degree of superficial microvacuolation was assessed using digital image analysis in the mFCtx and sTCtx. In most cases, at least some degree of microvacuolation was detected in both ROIs (Fig. [3](#acn350875-fig-0003){ref-type="fig"}). Quantitative analysis revealed that microvacuolation was more severe in FTLD‐GRN than FTLD‐C9ORF72, reaching statistical significance in mFCtx (*P* = 0.036).

![Cortical atrophy and superficial spongiosis in FTLD‐GRN and FTLD‐C9ORF72. Representative images of microvacuolation (MV) in superficial cortical layers of FTLD‐GRN (A) and FTLD‐C9ORF72 (B). Image analysis of the percent area of superficial cortex occupied by vacuoles (%). Vacuolation is significantly greater in FTLD‐GRN compared with FTLD‐C9ORF72 in middle frontal gyrus (mFCtx) (C), with a similar, but not statistically significant trend in the superior temporal gyrus (sTCtx) (D). Box plots show median (line) and 25th and 75th percentiles; whiskers show 10th and 90th percentiles. Bar indicates *P* \< 0.05 with Mann--Whitney *U* test. (Scale bar = 150 *µ*m).](ACN3-6-1782-g003){#acn350875-fig-0003}

### Neuroinflammation {#acn350875-sec-0026}

There were no significant differences in overall density of IBA‐1, CD68 and GFAP‐positive glial cells between FTLD‐C9ORF72 and FTLD‐GRN using digital image analysis in mFCTx, sTCTx, iPCTx, MCTx. The only exception was more CD68--positive microglia in the hippocampus in FTLD‐C9ORF72 (data not shown).

### Manual morphological assessment of IBA‐1-- and CD68--positive microglia {#acn350875-sec-0027}

Both FTLD‐GRN and FTLD‐C9ORF72 showed significantly fewer CD68‐high microglia than normal controls. FTLD‐GRN had significantly more rod--shaped microglia, and more microglia with condensed nuclei compared with both controls and FTLD‐C9ORF72 (*P* \< 0.001). FTLD‐GRN also had more IBA‐1‐positive and CD68‐positive rod‐shaped microglia than controls (*P* = 0.002). Compared to normal controls, both FTLD‐GRN and FTLD‐C9ORF72 had significantly more dystrophic microglia in mFCtx (Table [3](#acn350875-tbl-0003){ref-type="table"}). Interestingly, the number of total IBA‐1--positive cells in mFCtx was significantly greater in upper than lower cortical layers in FTLD‐GRN. In contrast, an minimally affected cortical region (MCtx), did not show any significant differences between FTLD‐GRN and FTLD‐C9ORF72 (Fig. [4](#acn350875-fig-0004){ref-type="fig"}). Superficial cortical layers in mFCtx not only had greater microvacuolation in FTLD‐GRN, but also significantly greater density of ameboid microglia compared with FTLD‐C9ORF72 (*P* = 0.025). Similarly, more ameboid microglia were detected in the deep white matter of mFCtx in FTLD‐GRN compared with FTLD‐C9ORF72 (*P* = 0.038). MCtx showed no significant difference between FTLD‐GRN and FTLD‐C9ORF72 (Fig. [5](#acn350875-fig-0005){ref-type="fig"}).

![Cortical IBA‐1--positive cells in FTLD‐GRN and FTLD‐C9ORF72. Representative images show entire cortical thickness of middle frontal gyrus (A and B) and superficial cortical layers (C and D) with IBA‐1 immunohistochemistry. Box plots (E and F) show the density of IBA‐1--positive cells in the upper and lower cortical layers by manual counts, relative to the entire region of interest. Box plots show median (line) and 25th and 75th percentiles; whiskers show 10th and 90th percentiles. Bars indicate *P* \< 0.05 with Mann--Whitney *U* test.](ACN3-6-1782-g004){#acn350875-fig-0004}

![IBA‐1--positive ameboid cells in FTLD‐GRN and FTLD‐C9ORF72. Comparison of ameboid microglia in superficial cortical layer (A and B) and subcortical white matter (C and D) of middle frontal gyrus (mFCtx) in FTLD‐GRN and FTLD‐C9ORF72. (Scale bar = 40 *µ*m). Density is the number of IBA‐1--positive ameboid microglia in superficial cortical layers (E) and subcortical white matter (F). Similar assessments in motor cortex (MCtx) show lower density of microglia in both superficial cortical layers (G) and subcortical white matter (H). Box plots show median (line) and 25th and 75th percentiles; whiskers show 10th and 90th percentiles. Bars indicate *P* \< 0.05 with Mann--Whitney *U* test.](ACN3-6-1782-g005){#acn350875-fig-0005}

Discussion {#acn350875-sec-0028}
==========

In this study, we compared FTLD‐GRN and FTLD‐C9ORF72 matched for TDP‐43 subtype (Type A) to exclude for differences due to TDP‐43 subtype. Although there are several clinical, neuropsychological, and radiological studies of FTLD‐GRN and C9ORF72, to our knowledge, this is the first direct clinicopathological comparison of FTLD‐GRN and FTLD‐C9ORF72 matched for TDP‐43 type.

In our clinical comparison, we found that FTLD‐C9ORF72 more frequently had amnestic dementia, including antemortem diagnoses of AD or DLB, as well as more symmetrical and milder cortical atrophy compared with FTLD‐GRN. Although amnestic deficits in FTD can be affected by executive dysfunction,[32](#acn350875-bib-0032){ref-type="ref"} our observations are in line with previous reports, including Mahoney and coworkers and Simon‐Sanchez and coworkers, who reported about half of FTLD‐C9ORF72 patients presented with memory impairment.[33](#acn350875-bib-0033){ref-type="ref"}, [34](#acn350875-bib-0034){ref-type="ref"} Our previous study showed FTLD‐C9ORF72 had greater tau pathology than FTLD‐GRN. A previous study showed less tau pathology in FTLD‐GRN compared to FTLD‐C9ORF72.[27](#acn350875-bib-0027){ref-type="ref"} In this study, we similarly found decreased tau densities in FTLD‐GRN in the mFCtx and hippocampus compared to FTLD‐C9ORF72. In line with this, Papegaey and coworkers biochemically reported reduction of tau protein expression in frontal cortex of FTLD‐GRN.[35](#acn350875-bib-0035){ref-type="ref"} We also found significant greater TDP‐43 in the hippocampus of FTLD‐C9ORF72 compared with FTLD‐GRN in addition to tau pathology. It is likely that hippocampal TDP‐43 pathology and tau pathology both contribute to the amnestic phenotype in FTLD‐C9ORF72.

FTLD‐GRN patients more often had asymmetrical clinical presentations, such as PNFA and CBS. This is in line with previous reports,[36](#acn350875-bib-0036){ref-type="ref"}, [37](#acn350875-bib-0037){ref-type="ref"} including a study by Pickering‐Brown and coworkers who reported that PNFA was more common in FTLD‐GRN (36%).[38](#acn350875-bib-0038){ref-type="ref"} FTLD‐GRN also had more severe cortical atrophy, microvacuolation, and more ameboid microglia in cortical regions (but not in the hippocampus) compared with FTLD‐C9ORF72. More severe and asymmetrical cortical atrophy, as well as greater TDP‐43 pathology in, sTCtx and iPCtx may underlie a pathological substrate of aphasia.

In the brain, expression studies based upon RNA sequencing show that it is extremely high in microglia and sparse in neurons.[39](#acn350875-bib-0039){ref-type="ref"} Loss of function mutations in *GRN*, leading to nonsense mediated decay of mRNA,[9](#acn350875-bib-0009){ref-type="ref"} are thought to be associated with microglial dysfunction.[40](#acn350875-bib-0040){ref-type="ref"}, [41](#acn350875-bib-0041){ref-type="ref"}

There are only a few quantitative neuropathologic studies on neuroinflammation in FTLD‐GRN and FTLD‐C9ORF72. Lant and coworkers performed a semiquantitative analysis of CD68--positive microglia in FTLD‐GRN (Type A), FTLD‐C9ORF72 (Types A and B) and FTLD‐MAPT in frontal and temporal cortices and found significantly more CD68--positive microglia in FTLD‐MAPT than in FTLD‐GRN and FTLD‐C9ORF72, but no difference between the two genetic forms of FTLD‐TDP.[42](#acn350875-bib-0042){ref-type="ref"}

In the present study, however, we assessed critically affected areas such as cortical layer II and also subtyped microglia based on morphology. We did not find any significant differences in rod--shaped or dystrophic microglia between FTLD‐GRN and FTLD‐C9ORF72, but showed that FTLD had significantly more dystrophic microglia compared to control. Several studies highlight a role for rod--shaped and dystrophic microglia in neurodegenerative diseases.[30](#acn350875-bib-0030){ref-type="ref"}, [43](#acn350875-bib-0043){ref-type="ref"}, [44](#acn350875-bib-0044){ref-type="ref"} The exact significance of these findings remain to be identified, but may be related to microglial dysfunction. On the other hand, FTLD‐GRN had more microglia with condensed nuclei, which may suggest either increased vulnerability of microglia deficient in GRN or an increased turnover of macrophages.

Furthermore, FTLD‐GRN had significantly more IBA‐1--positive ameboid cells in layer II of mFCtx and deep white matter. This is consistent with a study by Woollacott and coworkers reporting high density of amoeboid microglia in the cortex and white matter of a single FTLD‐GRN case.[45](#acn350875-bib-0045){ref-type="ref"} These findings suggest a role for ameboid microglia in the pathogenesis of both white matter and gray matter damage in FTLD‐GRN. FTLD‐GRN also showed more significant neocortical microvacuolation. The underlying molecular mechanism for microvacuolation is unknown, but synaptic damage has long been presumed to play a role.[46](#acn350875-bib-0046){ref-type="ref"} Lui and coworkers showed that progranulin knock‐out mice have synaptic loss through defective synaptic pruning by microglia.[40](#acn350875-bib-0040){ref-type="ref"} They also found increased IBA‐1--positive microglia in the frontal cortex of FTLD‐GRN compared with neurological controls.[40](#acn350875-bib-0040){ref-type="ref"} In conclusion, we found distinct clinicopathological differences between in FTLD‐GRN and FTLD‐C9ORF72 with respect to type A TDP‐43. Clinical asymmetric phenotypes, such as PNFA or CBS, as well as asymmetric brain atrophy, were more common in FTLD‐GRN. Early memory deficits and symmetric brain atrophy were more common in FTLD‐C9ORF72. Our neuropathological analyses highlight differential neocortical microvacuolation and phagocytic microglial phenotype between FTLD‐GRN and FTLD‐C9ORF72. Microglial dysfunction may be implicated in both mutations, but our data suggest different roles for neuroinflammation between FTLD‐GRN and FTLD‐C9ORF72. Additional experimental studies are warranted to better determine shared or distinct downstream mechanisms in microglial function associated with mutations in *C9orf72* and *GRN*. Furthermore, future clinicopathological studies should include comparative studies not only of FTLD Type A, which is found in a minority of C9ORF72 patients, and thus may not be representative of most C9ORF72 patients.
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